Search research articles
Contact Us
Filters
Showing results (141-150 of 159) with videos related to
Page
of 16
Sort By:
Rheumatology (Oxford, England)
|
December 26, 2025
Sex differences among patients with giant cell arteritis: insights from the Spanish ARTESER Registry
Delia Fernández-Lozano, Marta Domínguez-Álvaro, Javier Narváez, et al.
Science Translational Medicine
|
April 15, 2016
Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence
Justin M Balko, Luis J Schwarz, Na Luo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 17, 2019
Correction: ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors
Angel L Guerrero-Zotano, Thomas P Stricker, Luigi Formisano, et al.
Open Forum Infectious Diseases
|
March 3, 2022
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)
D Podzamczer, R Micán, J Tiraboschi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 28, 2018
ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors
Angel L Guerrero-Zotano, Thomas P Stricker, Luigi Formisano, et al.
Medicina Clinica (English Ed.)
|
October 11, 2021
Prognostic factors at admission on patients with cancer and COVID-19: Analysis of HOPE registry data
Pedro Pérez-Segura, M Paz-Cabezas, I J Núñez-Gil, et al.
Medicina Clinica
|
June 22, 2021
Prognostic factors at admission on patients with cancer and COVID-19: Analysis of HOPE registry data
Pedro Pérez-Segura, M Paz-Cabezas, I J Núñez-Gil, et al.
JCI Insight
|
December 21, 2018
Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement
Douglas B Johnson, Mellissa J Nixon, Yu Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 9, 2017
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
Bojana Jovanović, Ingrid A Mayer, Erica L Mayer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 17, 2019
Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
Sherene Loi, Sathana Dushyanthen, Paul A Beavis, et al.
Page
of 16
Search research articles
Search
Showing results (141-150 of 159) with videos related to
Sort By:
Page
of 16
Rheumatology (Oxford, England)
|
December 26, 2025
Sex differences among patients with giant cell arteritis: insights from the Spanish ARTESER Registry
Delia Fernández-Lozano, Marta Domínguez-Álvaro, Javier Narváez, et al.
Science Translational Medicine
|
April 15, 2016
Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence
Justin M Balko, Luis J Schwarz, Na Luo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 17, 2019
Correction: ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors
Angel L Guerrero-Zotano, Thomas P Stricker, Luigi Formisano, et al.
Open Forum Infectious Diseases
|
March 3, 2022
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)
D Podzamczer, R Micán, J Tiraboschi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 28, 2018
ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors
Angel L Guerrero-Zotano, Thomas P Stricker, Luigi Formisano, et al.
Medicina Clinica (English Ed.)
|
October 11, 2021
Prognostic factors at admission on patients with cancer and COVID-19: Analysis of HOPE registry data
Pedro Pérez-Segura, M Paz-Cabezas, I J Núñez-Gil, et al.
Medicina Clinica
|
June 22, 2021
Prognostic factors at admission on patients with cancer and COVID-19: Analysis of HOPE registry data
Pedro Pérez-Segura, M Paz-Cabezas, I J Núñez-Gil, et al.
JCI Insight
|
December 21, 2018
Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement
Douglas B Johnson, Mellissa J Nixon, Yu Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 9, 2017
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
Bojana Jovanović, Ingrid A Mayer, Erica L Mayer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 17, 2019
Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
Sherene Loi, Sathana Dushyanthen, Paul A Beavis, et al.
Page
of 16